There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
All content for Making Medicine is the property of Incubate Coalition and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
China’s Biotech Surge, GLP-1 Prices, & MFN Deadline | Press Pass with Max Bayer
Making Medicine
24 minutes
1 month ago
China’s Biotech Surge, GLP-1 Prices, & MFN Deadline | Press Pass with Max Bayer
In this week’s episode, John Stanford breaks down the White House autism event, the debate over shifting SEC reports to twice-yearly, and how MFN pressure is reshaping pricing strategy - before welcoming Endpoints News’ Max Bayer for a wide-ranging Press Pass on tariffs, GLP-1s, and China’s biotech surge. We unpack what “success” might look like for the administration’s drug-pricing push, why insurers could make or break any DTC effort, and how policy whiplash is hitting rare disease developers and investors. Max shares on-the-ground reporting about China’s rapidly built “Cambridge-like” ecosystems and the risks of restricting out-licensing. We also discuss the stakes for U.S. competitiveness if Europe becomes the default partner. Stick around to the end for how we’re tracking MFN and IRA signals across company filings.
Should SEC reporting shift to twice a year for biotechs, or does that cut needed transparency?
If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true
Follow Max Bayer https://www.linkedin.com/in/max-bayer-20435179
Timestamps: 0:05 Welcome to Making Medicine 0:36 Headlines: White House autism event & fallout 1:34 SEC filings: quarterly to semiannual debate 2:13 Press Pass: Max Bayer (Endpoints News) joins 2:39 “Totality” of actions - MFN, tariffs, vaccines, China deals 4:10 Investor lens: regulatory continuity & rare disease shocks 6:01 MFN behavior shifts (e.g., UK pricing moves) 8:39 What counts as success? GLP-1 pricing & insurer role 12:11 China’s biotech surge & the out-licensing boom 15:03 Policy options: restrictions vs. U.S. competitiveness (Europe risk) 17:20 U.S. ecosystem headwinds: jobs, patents, visas, funding 23:51 Outro, subscribe, and where to send tips for Max DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.
Making Medicine
There's a scientific breakthrough in your medicine cabinet. But how did it get there?
At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients.
From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures.
In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.
